Infectious Wound Care Management Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Therapeutics, Device), By Wound Type (Diabetes Mellitus, Hypoxia/Poor Tissue Perfusion, Other), By Region & Competition, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 1.54 Billion
CAGR (2026-2031)	7.22%
Fastest Growing Segment	Diabetes Mellitus
Largest Market	North America
Market Size (2031)	USD 2.34 Billion

Market Overview

The Global Infectious Wound Care Management Market is projected to grow from USD 1.54 Billion in 2025 to USD 2.34 Billion by 2031 at a 7.22% CAGR. Global infectious wound care management encompasses the comprehensive treatment of infected wounds utilizing specialized products such as antiseptics, advanced dressings, and therapeutic interventions to prevent complications and promote optimal healing. This market is significantly driven by a growing global aging population and the associated rise in chronic wounds, including diabetic foot ulcers and pressure sores, which necessitate ongoing care. Furthermore, increasing awareness of effective infection control practices among healthcare professionals and patients contributes substantially to market expansion.

A notable challenge impeding market growth is the escalating concern of antimicrobial resistance, which complicates the treatment of infectious wounds. According to the Association for Cleaning & Facility Solutions (ISSA), citing the World Health Organization in October 2025, an estimated 136 million cases of antimicrobial resistance-related healthcare-associated infections occur annually, underscoring the urgency for novel wound care solutions.

Key Market Drivers

Rising Prevalence of Chronic and Acute Wounds
The rising prevalence of chronic and acute wounds significantly propels the global infectious wound care management market. The increasing incidence of conditions such as diabetic foot ulcers, pressure injuries, and surgical site infections necessitates advanced solutions to prevent and treat infections and promote effective healing. For instance, Bonvadis® reported in May 2025 that in the United States, approximately 1.6 million people develop a diabetic foot ulcer each year, driving demand for specialized dressings, antiseptics, and therapeutic interventions. These complex wounds often require prolonged care and contribute substantially to healthcare burdens, thereby stimulating innovation and adoption of comprehensive wound care strategies.

Aging Population Driving Market Growth
Concurrently, the increasing geriatric population serves as another primary driver for market expansion. Older adults are inherently more susceptible to developing chronic wounds due to age-related physiological changes, comorbidities, and reduced mobility. According to data shared by the World Health Organization in February 2025, the population aged 60 and above is projected to increase from 1.1 billion in 2023 to 1.4 billion by 2030, which directly correlates with a larger patient pool requiring infectious wound care. This demographic shift intensifies the need for effective wound management products and services. The scale of this challenge is further underscored by Smith+Nephew reporting in May 2026 that chronic wounds affect up to 14.9 million people in Europe alone, consuming a substantial portion of healthcare expenditure.

Download Free Sample Report

Key Market Challenges

The escalating concern of antimicrobial resistance presents a significant impediment to the growth of the global infectious wound care management market. This challenge directly complicates the effective treatment of infected wounds, as pathogens develop resistance to existing antimicrobial agents, rendering conventional therapies less effective or entirely ineffective. Such resistance leads to prolonged healing times, increased patient suffering, and a heightened risk of severe complications, including sepsis and amputation.

The reduced efficacy of standard antimicrobial treatments necessitates the use of more aggressive, often more expensive, and sometimes less targeted interventions. This situation increases overall healthcare costs associated with wound management and places a substantial economic burden on healthcare systems globally. According to the Access to Medicine Foundation, in March 2026, more than one million people die each year as a direct result of drug-resistant infections, with antimicrobial resistance contributing to over four million deaths in total. This persistent threat restricts the market's ability to offer consistently reliable and cost-effective solutions, pushing demand towards innovative, yet often more complex and costly, advanced wound care products and specialized therapies.

Key Market Trends

The Global Infectious Wound Care Management Market is significantly influenced by ongoing advancements in antimicrobial and smart dressings. These innovations focus on developing products with enhanced capabilities such as sustained antimicrobial release, real-time wound condition monitoring, and adaptive microenvironments to optimize healing. Such sophisticated dressings aim to directly combat infection and improve patient outcomes by providing active therapeutic benefits beyond traditional protective barriers. According to Smith+Nephew's Fourth Quarter and Full Year 2025 Results, published March 2, 2026, their Advanced Wound Management segment recorded an underlying revenue growth of 2.8% in Q4 2025, reflecting continued demand and investment in this innovative product category.

Another pivotal trend is the increasing integration of digital health and telehealth solutions for wound care. These technologies enable remote wound assessment, virtual consultations, and digital tracking of healing progress, thereby enhancing accessibility to specialized care and facilitating timely interventions. This shift towards digitally-enabled care models supports efficient management of infectious wounds in diverse settings, including home healthcare. Illustrating the effectiveness of such approaches in promoting patient engagement and adherence, Smith+Nephew reported in May 2026 that its RENASYS™ EDGE Negative Pressure Wound Therapy system achieved an average of 88% therapy session patient compliance. This highlights how advanced portable devices, integrated with care pathways, empower patients in their treatment.

Segmental Insights

The Diabetes Mellitus segment is identified as the fastest-growing area within the Global Infectious Wound Care Management Market. This rapid expansion is primarily driven by the escalating global prevalence of diabetes, which significantly contributes to an increased incidence of chronic diabetic foot ulcers and other non-healing wounds. These conditions often lead to complications requiring specialized infectious wound care management. The rising number of individuals living with diabetes, as reported by organizations like the International Diabetes Federation, underscores the persistent demand for effective solutions to manage associated infectious wounds, thereby fueling substantial market growth in this segment.

Regional Insights

North America stands as the dominant region in the Global Infectious Wound Care Management Market, holding a leading market share due to its sophisticated healthcare infrastructure and significant healthcare expenditure. The region benefits from a high incidence of chronic diseases, such as diabetes, which contribute considerably to the burden of infectious wounds. Robust regulatory frameworks, including those established by the U.S. Food and Drug Administration, facilitate the adoption of innovative wound care products and therapies. Additionally, the strong presence of key market players focused on research and development, coupled with favorable reimbursement policies, further solidifies North America's leadership in advancing infectious wound management solutions.

Recent Developments

• In May 2026, Smith+Nephew introduced two new wound care innovations, ALLEVYN COMPLETE CARE Foam Dressing and RENASYS EDGE Negative Pressure Wound Therapy System, at the EWMA conference. These products were designed to enhance chronic wound management, intending to improve patient outcomes, simplify care, and reduce clinical burden. The ALLEVYN COMPLETE CARE dressing featured a five-layer design to support wound healing and pressure ulcer prevention, which is vital for mitigating infection risks. RENASYS EDGE provided a portable system emphasizing patient compliance and low maintenance, advancing the management of complex wounds where infection control is critical.
• In May 2026, Dimora Medical launched an advanced sacral dressing developed to address pressure injuries. This new Sacrum Silicone Absorbent Soft Dressing featured an extended tail-wing shape, providing enhanced coverage for the sacral area, a common site for pressure injury development. The dressing incorporated a superabsorbent polymer composite core capable of absorbing over 20 times its weight in fluid rapidly. This functionality was essential for managing wound exudate, thereby reducing the risk of maceration and subsequent infection, and promoting efficient healing in patients with limited mobility.
• In December 2025, Tiger BioSciences highlighted significant clinical and scientific achievements resulting from its expanded investments in evidence-based research throughout the year. The company showcased peer-reviewed retrospective clinical studies that affirmed the effectiveness of its product, completeFT, in advanced wound management. Additionally, early findings from an ongoing randomized controlled trial evaluating caregraFT for diabetic foot ulcers and venous leg ulcers demonstrated promising clinical outcomes. This research underscored the potential of caregraFT as a next-generation option for chronic wound care, addressing conditions often associated with infectious complications.
• In October 2025, Clyra Medical Technologies, a subsidiary of BioLargo, Inc., prepared for the commercial debut of its ViaCLYR product. This advanced solution for wound irrigation and antimicrobial treatment was expected to launch in late 2025 or early 2026. The company expanded its distribution agreements into the Europe-Middle East-Africa region, aiming to increase global access to its infection prevention and wound management offerings. Furthermore, Clyra secured over US$7.5 million in funding to support capital investments, product launches, and market expansion. These strategic initiatives aimed to diversify its antimicrobial and wound care products across various medical markets.

Key Market Players

• Molnlycke Health Care AB
• Hartmann Group
• Smith & Nephew PLC
• 3M Company.
• Smith & Nephew PLC
• Medtronic Plc
• B Braun Melsungen AG
• Johnson & Johnson
• Molnlycke Healthcare AB
• Conva Tec Inc.

By Product Type	By Wound Type	By Region
Therapeutics Device	Diabetes Mellitus Hypoxia/Poor Tissue Perfusion Other	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Infectious Wound Care Management Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Infectious Wound Care Management Market, By Product Type:

• Therapeutics
• Device

• Infectious Wound Care Management Market, By Wound Type:

• Diabetes Mellitus
• Hypoxia/Poor Tissue Perfusion
• Other

• Infectious Wound Care Management Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE